Page 6 - William Levine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

After 42 years, Columbia trainer Jim Gossett retires After 42 years, Columbia trainer Jim Gossett retires Carlos Ochoa / Senior Staff Illustrator Since 1979, Jim Gossett has served as a trainer for Columbia Athletics teams like men’s soccer, wrestling, lightweight crew, fencing, and football—becoming one of the country’s highest regarded athletics trainers. By Wick Hallos | April 27, 2021, 11:17 PM When Jim Gossett announced that he would be retiring from his positions as associate athletics director for sports medicine and head athletics trainer, he began to receive an outpouring...

Plus Products Partners with CannRx Biosciences to Leverage Proprietary Onset Technology Plus Products Partners with CannRx Biosciences to Leverage Proprietary Onset Technology SAN MATEO, Calif., Feb. 04, 2021 — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a cannabis and hemp branded products company in the U.S., today announced that it has entered into a partnership with CannRx Biosciences (“CannRx”), a leading Israeli cannabis firm in the boutique field of cannabis-based botanical medicine, to enhance the onset of the Company’s products. CannRx, o...

  “Stacking rings are huge right now for wedding bands. Different metals, mixing and matching, is really, really hot. You can change them up based on what you feel like that day. They can also constantly add bands to the story.” (Top) 14k gold mounting, milgrain band, and diamond eternity and anniversary bands; $768–$1,674; “Stretchy bracelets are very easy. They’re durable, flexible, and versatile. Platini or Fope make them. They are mainly gold but can be gold with diamonds or ceramic, too. You can mix them and create a personalized look.” Hoop Sweet 14k Strawberry Gold earrin...

Health Canada’s approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials – VIALE-A and VIALE-C 1 . The VIALE-A trial demonstrated a statistically significant increase in overall survival with VENCLEXTA in combination with azacitidine compared to azacitidine alone. 1 In the VIALE-C trial, clinical benefit was based on rate and … Health Canada’s approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials – VIA...